Therapeutic Options in Locally Advanced Thymoma

  • Patrick J. Loehrer
  • Mauro Antimi
  • Andrew Turrisi
  • Giuseppe Giaccone


Thymoma is the most common tumor of the anterior mediastinum. Most thymomas will present as a well encapsulated tumor which can be resected for cure in 80–90% of patients. Many of these patients have paraneoplastic syndromes such as myasthenia gravis, hypogammaglobulinemia, or pure red cell aplasia, which others may have symptom of local disease such as chest pain or superior vena caval obstruction. About one-third of patients present with asymptomatic mass on chest radiograph which ultimately prompts further evaluation.1


Clin Oncol Eastern Cooperative Oncology Group Objective Response Rate Thymic Carcinoma Combine Modality Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Loehrer PJ: Thymomas. Current experience and future directions in therapy. Drugs 45(4):477-487, 1993.Google Scholar
  2. 2.
    Levine GD and Rosai J: Thymic hyperplasia and neoplasia: A review of current concepts. Hum Pathol 9:494–515, 1978.CrossRefGoogle Scholar
  3. 3.
    Verley JM and Hollman KH: Thymoma: A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer 55:1074–1086, 1985.PubMedCrossRefGoogle Scholar
  4. 4.
    Lewis JE, Wick MR, Scheithauer BW, et al: Thymoma: A Clinicopathologic review. Cancer 60:2727–2743, 1987.PubMedCrossRefGoogle Scholar
  5. 5.
    Marino M and Müller-Hermelink HK: Thymoma and thymic carcinoma. Virchows Arch A Pathol Anat Histopathol 407:119–149, 1985.PubMedCrossRefGoogle Scholar
  6. 6.
    Debono DJ and Loehrer PJ: Thymic neoplasms. Current Opinion in Oncology 8:112–119, 1996.PubMedCrossRefGoogle Scholar
  7. 7.
    Masaoka A, Monden Y, Nakahara K, et al: Follow-up study of thymomas with special reference to their clinical stage. Cancer 48:2485–2492, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Yamakawa Y, Masaoka A, Hashimoto T, et al: A tentative tumor-node-metastasis classification of thymoma. Cancer 68:1984–1987, 1991.PubMedCrossRefGoogle Scholar
  9. 9.
    Wilkins WE Jr and Castleman B: A continuing survey at the Massachusetts General Hospital. Ann Thorac Surg 28:252–2256, 1979.PubMedCrossRefGoogle Scholar
  10. 10.
    Wilkins EW Jr, Grillo HC, Scannell JG, et al: Role of Staging in Prognosis and Management of Thymoma (J Maxwell Chamberlain Memorial Paper). Ann Thorac Surg 51:888–892, 1991.PubMedCrossRefGoogle Scholar
  11. 11.
    Lewis JE, Wick MR, Scheithauer BW, et al: Thymoma, A clinicopathologic review. Cancer 60:2727–2743, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    Curran WJ, Kornstein MJ, Brooks JJ, et al: Invasive thymoma: The role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6:1722–1727, 1988.PubMedGoogle Scholar
  13. 13.
    Koh W-J, Loehrer PJ, Thomas C: Thymoma: Radiation and chemotherapy. In Mediastinal Tumors: Update 1995. Edited by Wood DE, Thomas CR. New York: Springer-Verlag; 1995, 19–25.CrossRefGoogle Scholar
  14. 14.
    Bonomi PD, Finkelstein D, Aisner S, et al: EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 16:342–345, 1993.PubMedCrossRefGoogle Scholar
  15. 15.
    Harper PG, Highley M, Rankin E, et al: Ifosfamide monotherapy demonstrates high activity in malignant thymoma (abstract). Proc Am Soc Clin Oncol 10:300, 1991.Google Scholar
  16. 16.
    Berthaud P, le Chevalier T, Tursz T: Effective of Interleukin-2 in invasive lymphoepithelial thymoma (letter). Lancet 335:1590, 1990.PubMedCrossRefGoogle Scholar
  17. 17.
    Gordon MS, Battiato LA, Gonin R, et al: A phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed/refractory thymoma. J Immunother 1996 (in press).Google Scholar
  18. 18.
    Loehrer PJ, Kim K, Aisner SC, et al: Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: finalresults of an intergroup trial. J Clin Oncol 12:1164–1168, 1994.PubMedGoogle Scholar
  19. 19.
    Loehrer PJ, Kim K, Chen M, et al: Phase II trial of cisplatin (P), adriamycin (A), cyclophosphamide (C) plus radiotherapy in limited stage unresectable thymoma (abstract 1375). Proc Am Soc Clin Oncol 14:433, 1995.Google Scholar
  20. 20.
    Fornasiero A, Daniele O, Ghiotto C, et al: Chemotherapy of Invasive thymoma. J Clin Oncol 8:1419–1423, 1990.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Patrick J. Loehrer
    • 1
  • Mauro Antimi
    • 2
  • Andrew Turrisi
    • 3
  • Giuseppe Giaccone
    • 4
  1. 1.Indiana University Medical Center, Indiana University HospitalIndianapolisUSA
  2. 2.USL Rm 7, Ospedele San EugenioOnco-Ematologica/Servisio OncologicoRomeItaly
  3. 3.Department of Radiation OncologyMedical University of South CarolinaCharlestonUSA
  4. 4.Department of OncologyFree University HospitalAmsterdamThe Netherlands

Personalised recommendations